Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat vs allopurinol in gout hyperuricemia (Phase II, China)
CTR20131461Phase 2Completed
- Sponsor
- China Resources Double-Crane Pharmaceutical
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of febuxostat in gout and hyperuricemia (2 arms), sponsored by China Resources Double-Crane Pharmaceutical. Primary endpoint: Proportion of patients achieving sUA ≤ 6.0 mg/dL at last measurement within 24 weeks. Started Apr 2014; status: completed.
02
Drugs
febuxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20131461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131461.